BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 13, 2007
View Archived Issues
Experiments reveal characteristics of GA2-50, a possible treatment for cocaine abuse
Read More
Less toxicity seen with ISA-247 than with ciclosporin in vitro
Read More
Natural products in dermatology
Read More
UC Davis and M.I.N.D. Institute awarded grant for Fragile X research / News in Context
Read More
Palatin reacquires full rights to bremelanotide program
Read More
BrainStorm Cell Therapeutics takes initial steps toward FDA IND submission
Read More
Ownership of GI motility dysfunction program and TD-1792 retained by Theravance
Read More
Data from Accentia's phase III trial suggest fungal-induced inflammation as cause of CS
Read More
FDA grants Bioniche SPA for phase III study of MCC for bladder cancer
Read More
Update on Welichem's phase I trials of WBI-1001 for psoriasis
Read More
FDA extends review period of sNDA of Frova for short-term prevention of menstrual migraine
Read More
Ariad and FDA agree on SPA for phase III trial of deforolimus for metastatic sarcomas
Read More
Positive results for Moberg Derma's phase II trial of K-301 for seborrheic dermatitis
Read More
Basilea submits MAA for oral alitretinoin for chronic hand eczema in Europe
Read More
Novel therapeutic options for obesity and metabolic diseases described in recent patents
Read More
Wyeth and Progenics begin clinical trials of subcutaneous and intravenous methylnaltrexone
Read More
Novel agents for cardiovascular disorders disclosed in recent Takeda and Pfizer patents
Read More
Novel treatments for musculoskeletal and connective tissue disorders claimed in recent patents
Read More
Indolent NHL subject of Cell Therapeutics' phase III trial with pixantrone
Read More
EDSMB encourages continuation of phase III trial with Arena's lorcaserin
Read More
Promising phase II results with TPI-1020 support potential COPD trial
Read More
Wake-promoting profile of a novel histamine H3 antagonist
Read More
Auxilium begins dosing patients in two phase III trials of Xiaflex
Read More
Merck & Co. completes acquisition of NovaCardia
Read More
Astellas Pharma evaluates ASP-0485 for new indication
Read More